世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
骨粗鬆症治療薬市場。世界の産業動向、シェア、サイズ、成長、機会、および2021-2026年の予測Osteoporosis Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026 The global osteoporosis drugs market grew at a CAGR of around 5% during 2015-2020. Osteoporosis is a disease that causes deterioration of bone tissues and strength. It is diagnosed by performing di... もっと見る
サマリーThe global osteoporosis drugs market grew at a CAGR of around 5% during 2015-2020. Osteoporosis is a disease that causes deterioration of bone tissues and strength. It is diagnosed by performing different scans, such as X-ray, computed tomography (CT) and magnetic resonance imaging (MRI). Various drugs are currently available in different formulations, ranging from regular tablets to intravenous (IV) infusions, for alleviating the symptoms of osteoporosis. These drugs help restore the balance of resorption and formation, repair microscopic defects in bones, reduce the risk of fractures and improve the overall muscle strength of the patients.The growing prevalence of osteoporosis on account of sedentary lifestyles, excessive consumption of alcohol, and rising utilization of tobacco represent the key factors bolstering the growth of the market. The increasing number of individuals who have celiac disease, kidney or liver disease, cancer, lupus, multiple myeloma and rheumatoid arthritis is further accelerating the market growth. Moreover, bone mass loss increases with age, which raises the risk of developing osteoporosis among older people. Consequently, the rising geriatric population is positively influencing the demand for osteoporosis drugs worldwide. Furthermore, several governing authorities are developing novel therapeutics, which is contributing to the market growth. For instance, the US Food and Drug Administration (FDA) has approved novel osteoporosis drugs for postmenopausal women who are at a high risk of fractures or are intolerant to other osteoporosis therapies. Besides this, a wide range of drugs in late-stage clinical trials is anticipated to propel the market growth in the coming years. Looking forward, IMARC Group expects the global osteoporosis drugs market to exhibit moderate growth during the next five years. Key Market Segmentation: IMARC Group provides an analysis of the key trends in each sub-segment of the global osteoporosis drugs market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, product type and route of administration. Breakup by Product Type: Bisphosphonates Calcitonin Rank Ligand Inhibitor Parathyroid Hormone Therapy (PTH) Selective Estrogen Receptor Modulators (SERMs) Sclerostin Inhibitor Others Breakup by Route of Administration: Oral Injectable Others Breakup by Region: North America United States Canada Asia-Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa Competitive Landscape: The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd. and UCB S.A. Key Questions Answered in This Report: How has the global osteoporosis drugs market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global osteoporosis drugs market? What are the key regional markets? What is the breakup of the market based on the product type? What is the breakup of the market based on the route of administration? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global osteoporosis drugs market and who are the key players? What is the degree of competition in the industry? 目次1 Preface2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Osteoporosis Drugs Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Product Type 6.1 Bisphosphonates 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Calcitonin 6.2.1 Market Trends 6.2.2 Market Forecast 6.3 Rank Ligand Inhibitor 6.3.1 Market Trends 6.3.2 Market Forecast 6.4 Parathyroid Hormone Therapy (PTH) 6.4.1 Market Trends 6.4.2 Market Forecast 6.5 Selective Estrogen Receptor Modulators (SERMs) 6.5.1 Market Trends 6.5.2 Market Forecast 6.6 Sclerostin Inhibitor 6.6.1 Market Trends 6.6.2 Market Forecast 6.7 Others 6.7.1 Market Trends 6.7.2 Market Forecast 7 Market Breakup by Route of Administration 7.1 Oral 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Injectable 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Others 7.3.1 Market Trends 7.3.2 Market Forecast 8 Market Breakup by Region 8.1 North America 8.1.1 United States 8.1.1.1 Market Trends 8.1.1.2 Market Forecast 8.1.2 Canada 8.1.2.1 Market Trends 8.1.2.2 Market Forecast 8.2 Asia-Pacific 8.2.1 China 8.2.1.1 Market Trends 8.2.1.2 Market Forecast 8.2.2 Japan 8.2.2.1 Market Trends 8.2.2.2 Market Forecast 8.2.3 India 8.2.3.1 Market Trends 8.2.3.2 Market Forecast 8.2.4 South Korea 8.2.4.1 Market Trends 8.2.4.2 Market Forecast 8.2.5 Australia 8.2.5.1 Market Trends 8.2.5.2 Market Forecast 8.2.6 Indonesia 8.2.6.1 Market Trends 8.2.6.2 Market Forecast 8.2.7 Others 8.2.7.1 Market Trends 8.2.7.2 Market Forecast 8.3 Europe 8.3.1 Germany 8.3.1.1 Market Trends 8.3.1.2 Market Forecast 8.3.2 France 8.3.2.1 Market Trends 8.3.2.2 Market Forecast 8.3.3 United Kingdom 8.3.3.1 Market Trends 8.3.3.2 Market Forecast 8.3.4 Italy 8.3.4.1 Market Trends 8.3.4.2 Market Forecast 8.3.5 Spain 8.3.5.1 Market Trends 8.3.5.2 Market Forecast 8.3.6 Russia 8.3.6.1 Market Trends 8.3.6.2 Market Forecast 8.3.7 Others 8.3.7.1 Market Trends 8.3.7.2 Market Forecast 8.4 Latin America 8.4.1 Brazil 8.4.1.1 Market Trends 8.4.1.2 Market Forecast 8.4.2 Mexico 8.4.2.1 Market Trends 8.4.2.2 Market Forecast 8.4.3 Others 8.4.3.1 Market Trends 8.4.3.2 Market Forecast 8.5 Middle East and Africa 8.5.1 Market Trends 8.5.2 Market Breakup by Country 8.5.3 Market Forecast 9 SWOT Analysis 9.1 Overview 9.2 Strengths 9.3 Weaknesses 9.4 Opportunities 9.5 Threats 10 Value Chain Analysis 11 Porters Five Forces Analysis 11.1 Overview 11.2 Bargaining Power of Buyers 11.3 Bargaining Power of Suppliers 11.4 Degree of Competition 11.5 Threat of New Entrants 11.6 Threat of Substitutes 12 Price Analysis 13 Competitive Landscape 13.1 Market Structure 13.2 Key Players 13.3 Profiles of Key Players 13.3.1 Amgen Inc. 13.3.1.1 Company Overview 13.3.1.2 Product Portfolio 13.3.1.3 Financials 13.3.1.4 SWOT Analysis 13.3.2 Eli Lilly and Company 13.3.2.1 Company Overview 13.3.2.2 Product Portfolio 13.3.2.3 Financials 13.3.2.4 SWOT Analysis 13.3.3 F. Hoffmann-La Roche AG 13.3.3.1 Company Overview 13.3.3.2 Product Portfolio 13.3.3.3 SWOT Analysis 13.3.4 GlaxoSmithKline Plc 13.3.4.1 Company Overview 13.3.4.2 Product Portfolio 13.3.4.3 Financials 13.3.4.4 SWOT Analysis 13.3.5 Merck & Co. Inc. 13.3.5.1 Company Overview 13.3.5.2 Product Portfolio 13.3.5.3 Financials 13.3.5.4 SWOT Analysis 13.3.6 Novartis AG 13.3.6.1 Company Overview 13.3.6.2 Product Portfolio 13.3.6.3 Financials 13.3.6.4 SWOT Analysis 13.3.7 Pfizer Inc. 13.3.7.1 Company Overview 13.3.7.2 Product Portfolio 13.3.7.3 Financials 13.3.7.4 SWOT Analysis 13.3.8 Radius Health Inc. 13.3.8.1 Company Overview 13.3.8.2 Product Portfolio 13.3.8.3 Financials 13.3.9 Teva Pharmaceutical Industries Ltd. 13.3.9.1 Company Overview 13.3.9.2 Product Portfolio 13.3.9.3 Financials 13.3.9.4 SWOT Analysis 13.3.10 UCB S.A. 13.3.10.1 Company Overview 13.3.10.2 Product Portfolio 13.3.10.3 Financials 13.3.10.4 SWOT Analysis
SummaryThe global osteoporosis drugs market grew at a CAGR of around 5% during 2015-2020. Osteoporosis is a disease that causes deterioration of bone tissues and strength. It is diagnosed by performing different scans, such as X-ray, computed tomography (CT) and magnetic resonance imaging (MRI). Various drugs are currently available in different formulations, ranging from regular tablets to intravenous (IV) infusions, for alleviating the symptoms of osteoporosis. These drugs help restore the balance of resorption and formation, repair microscopic defects in bones, reduce the risk of fractures and improve the overall muscle strength of the patients.The growing prevalence of osteoporosis on account of sedentary lifestyles, excessive consumption of alcohol, and rising utilization of tobacco represent the key factors bolstering the growth of the market. The increasing number of individuals who have celiac disease, kidney or liver disease, cancer, lupus, multiple myeloma and rheumatoid arthritis is further accelerating the market growth. Moreover, bone mass loss increases with age, which raises the risk of developing osteoporosis among older people. Consequently, the rising geriatric population is positively influencing the demand for osteoporosis drugs worldwide. Furthermore, several governing authorities are developing novel therapeutics, which is contributing to the market growth. For instance, the US Food and Drug Administration (FDA) has approved novel osteoporosis drugs for postmenopausal women who are at a high risk of fractures or are intolerant to other osteoporosis therapies. Besides this, a wide range of drugs in late-stage clinical trials is anticipated to propel the market growth in the coming years. Looking forward, IMARC Group expects the global osteoporosis drugs market to exhibit moderate growth during the next five years. Key Market Segmentation: IMARC Group provides an analysis of the key trends in each sub-segment of the global osteoporosis drugs market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, product type and route of administration. Breakup by Product Type: Bisphosphonates Calcitonin Rank Ligand Inhibitor Parathyroid Hormone Therapy (PTH) Selective Estrogen Receptor Modulators (SERMs) Sclerostin Inhibitor Others Breakup by Route of Administration: Oral Injectable Others Breakup by Region: North America United States Canada Asia-Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa Competitive Landscape: The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd. and UCB S.A. Key Questions Answered in This Report: How has the global osteoporosis drugs market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global osteoporosis drugs market? What are the key regional markets? What is the breakup of the market based on the product type? What is the breakup of the market based on the route of administration? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global osteoporosis drugs market and who are the key players? What is the degree of competition in the industry? Table of Contents1 Preface2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Osteoporosis Drugs Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Product Type 6.1 Bisphosphonates 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Calcitonin 6.2.1 Market Trends 6.2.2 Market Forecast 6.3 Rank Ligand Inhibitor 6.3.1 Market Trends 6.3.2 Market Forecast 6.4 Parathyroid Hormone Therapy (PTH) 6.4.1 Market Trends 6.4.2 Market Forecast 6.5 Selective Estrogen Receptor Modulators (SERMs) 6.5.1 Market Trends 6.5.2 Market Forecast 6.6 Sclerostin Inhibitor 6.6.1 Market Trends 6.6.2 Market Forecast 6.7 Others 6.7.1 Market Trends 6.7.2 Market Forecast 7 Market Breakup by Route of Administration 7.1 Oral 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Injectable 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Others 7.3.1 Market Trends 7.3.2 Market Forecast 8 Market Breakup by Region 8.1 North America 8.1.1 United States 8.1.1.1 Market Trends 8.1.1.2 Market Forecast 8.1.2 Canada 8.1.2.1 Market Trends 8.1.2.2 Market Forecast 8.2 Asia-Pacific 8.2.1 China 8.2.1.1 Market Trends 8.2.1.2 Market Forecast 8.2.2 Japan 8.2.2.1 Market Trends 8.2.2.2 Market Forecast 8.2.3 India 8.2.3.1 Market Trends 8.2.3.2 Market Forecast 8.2.4 South Korea 8.2.4.1 Market Trends 8.2.4.2 Market Forecast 8.2.5 Australia 8.2.5.1 Market Trends 8.2.5.2 Market Forecast 8.2.6 Indonesia 8.2.6.1 Market Trends 8.2.6.2 Market Forecast 8.2.7 Others 8.2.7.1 Market Trends 8.2.7.2 Market Forecast 8.3 Europe 8.3.1 Germany 8.3.1.1 Market Trends 8.3.1.2 Market Forecast 8.3.2 France 8.3.2.1 Market Trends 8.3.2.2 Market Forecast 8.3.3 United Kingdom 8.3.3.1 Market Trends 8.3.3.2 Market Forecast 8.3.4 Italy 8.3.4.1 Market Trends 8.3.4.2 Market Forecast 8.3.5 Spain 8.3.5.1 Market Trends 8.3.5.2 Market Forecast 8.3.6 Russia 8.3.6.1 Market Trends 8.3.6.2 Market Forecast 8.3.7 Others 8.3.7.1 Market Trends 8.3.7.2 Market Forecast 8.4 Latin America 8.4.1 Brazil 8.4.1.1 Market Trends 8.4.1.2 Market Forecast 8.4.2 Mexico 8.4.2.1 Market Trends 8.4.2.2 Market Forecast 8.4.3 Others 8.4.3.1 Market Trends 8.4.3.2 Market Forecast 8.5 Middle East and Africa 8.5.1 Market Trends 8.5.2 Market Breakup by Country 8.5.3 Market Forecast 9 SWOT Analysis 9.1 Overview 9.2 Strengths 9.3 Weaknesses 9.4 Opportunities 9.5 Threats 10 Value Chain Analysis 11 Porters Five Forces Analysis 11.1 Overview 11.2 Bargaining Power of Buyers 11.3 Bargaining Power of Suppliers 11.4 Degree of Competition 11.5 Threat of New Entrants 11.6 Threat of Substitutes 12 Price Analysis 13 Competitive Landscape 13.1 Market Structure 13.2 Key Players 13.3 Profiles of Key Players 13.3.1 Amgen Inc. 13.3.1.1 Company Overview 13.3.1.2 Product Portfolio 13.3.1.3 Financials 13.3.1.4 SWOT Analysis 13.3.2 Eli Lilly and Company 13.3.2.1 Company Overview 13.3.2.2 Product Portfolio 13.3.2.3 Financials 13.3.2.4 SWOT Analysis 13.3.3 F. Hoffmann-La Roche AG 13.3.3.1 Company Overview 13.3.3.2 Product Portfolio 13.3.3.3 SWOT Analysis 13.3.4 GlaxoSmithKline Plc 13.3.4.1 Company Overview 13.3.4.2 Product Portfolio 13.3.4.3 Financials 13.3.4.4 SWOT Analysis 13.3.5 Merck & Co. Inc. 13.3.5.1 Company Overview 13.3.5.2 Product Portfolio 13.3.5.3 Financials 13.3.5.4 SWOT Analysis 13.3.6 Novartis AG 13.3.6.1 Company Overview 13.3.6.2 Product Portfolio 13.3.6.3 Financials 13.3.6.4 SWOT Analysis 13.3.7 Pfizer Inc. 13.3.7.1 Company Overview 13.3.7.2 Product Portfolio 13.3.7.3 Financials 13.3.7.4 SWOT Analysis 13.3.8 Radius Health Inc. 13.3.8.1 Company Overview 13.3.8.2 Product Portfolio 13.3.8.3 Financials 13.3.9 Teva Pharmaceutical Industries Ltd. 13.3.9.1 Company Overview 13.3.9.2 Product Portfolio 13.3.9.3 Financials 13.3.9.4 SWOT Analysis 13.3.10 UCB S.A. 13.3.10.1 Company Overview 13.3.10.2 Product Portfolio 13.3.10.3 Financials 13.3.10.4 SWOT Analysis
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（生化学的薬物）の最新刊レポートIMARC Services Private Limited.社のその他分野での最新刊レポート
本レポートと同じKEY WORD（industry）の最新刊レポート
よくあるご質問IMARC Services Private Limited.社はどのような調査会社ですか?インドに調査拠点を持つ調査会社。幅広い分野をカバーしていますがケミカルに特に焦点を当てています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/21 10:26 156.13 円 165.08 円 200.38 円 |
